Healthcare -
Biotechnology - NASDAQ - US
$ 23.214
-2.99 %
$ 1.48 B
Market Cap
-7.68
P/E
1. INTRINSIC VALUE
Balance Sheet
Vera Therapeutics, Inc.
| Current Assets | 651 M |
| Cash & Short-Term Investments | 641 M |
| Receivables | 3.77 M |
| Other Current Assets | 6.59 M |
| Non-Current Assets | 4.46 M |
| Long-Term Investments | 0 |
| PP&E | 4.33 M |
| Other Non-Current Assets | 131 K |
| Current Liabilities | 25.4 M |
| Accounts Payable | 7.66 M |
| Short-Term Debt | 1.48 M |
| Other Current Liabilities | 16.2 M |
| Non-Current Liabilities | 53.2 M |
| Long-Term Debt | 53.2 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Vera Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 167 M |
| Operating Income | -167 M |
| Other Expenses | -15 M |
| Net Income | -152 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Vera Therapeutics, Inc.
| Net Income | -152 M |
| Depreciation & Amortization | 105 K |
| Capital Expenditures | -972 K |
| Stock-Based Compensation | 20.8 M |
| Change in Working Capital | 2.66 M |
| Others | 15 K |
| Free Cash Flow | -136 M |
Wall Street Analysts Price Targets
Vera Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for VERA of $39.3 , with forecasts ranging from
a
low of
$6 to a high of $65 .
VERA Lowest Price Target
Wall Street Target
6 USD
-74.15%
VERA Average Price Target
Wall Street Target
39.3 USD
69.44%
VERA Highest Price Target
Wall Street Target
65 USD
180.00%
4. DIVIDEND
ANALYSIS
VERA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Vera Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
547 K USD 1
6-9 MONTHS
6.25 M USD 2
9-12 MONTHS
5.18 M USD 2
Bought
5.28 M USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif. , July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 133,500 shares of Class A common stock and restricted stock units (RSUs) for 73,695 shares of Class A common stock to fifteen (15) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
globenewswire.com
- 2 weeks ago
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
The biopharmaceuticals industry is both exciting and risky for investors. Many leading growth stocks in the U.S. market are found in this sector, due to the significant rallies that biopharmaceutical companies experience when a key positive trial result is announced or an important drug receives government approval.
marketbeat.com
- 1 month ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted stock units (RSUs) for 65,925 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
globenewswire.com
- 1 month ago
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami Beach, FL from June 9 – 11, 2025. The management team will also participate in one-on-one investor meetings.
globenewswire.com
- 1 month ago
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
BRISBANE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has entered into a new credit facility providing for up to $500 million of term loans with its current partner Oxford Finance LLC (“Oxford”). The new credit facility will replace Vera's existing $50 million credit facility. The initial funding of the new credit facility will be in a principal amount of $75 million and is expected to occur on June 4, 2025.
globenewswire.com
- 1 month ago
Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data
Vera Therapeutics, Inc. VERA saw its share price surge over 65% during the pre-market trading session on Monday after the company released ORIGIN Phase 3 trial data.
benzinga.com
- 1 month ago
Vera shares skyrocket as kidney disease drug succeeds in late-stage trial
Shares of Vera Therapeutics soared 82% on Monday, after the company said its experimental drug helped significantly reduce excess levels of harmful proteins in the urine of kidney disease patients in a late-stage study.
reuters.com
- 1 month ago
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
BRISBANE, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that the primary endpoint was met in the ORIGIN Phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy (IgAN) in adults.
globenewswire.com
- 1 month ago
Vera Therapeutics: Huge Catalyst Upcoming For Kidney Disease Drug
I am maintaining my 'Hold' rating on Vera Therapeutics from January 2024 despite initial strong stock gains and positive Phase 2b data for atacicept, before a collapse in stock value. In my last note, I cited high short interest, lack of other assets, and long timeline for approval as key reasons for caution. Vera's pivotal Phase 3 trial data is likely to be shared in the next month, however, presenting a potentially momentous catalyst, and an approval shot in 2026.
seekingalpha.com
- 2 months ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 5, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 111,750 shares of Class A common stock and restricted stock units (RSUs) for 62,575 shares of Class A common stock to eleven (11) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
globenewswire.com
- 2 months ago
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
On track to announce the primary endpoint results from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; planning for Biologics License Application (BLA) submission for atacicept accelerated approval to the U.S. FDA in 4Q 2025 Expanded atacicept development program across multiple autoimmune kidney diseases is underway BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the first quarter ended March 31, 2025.
globenewswire.com
- 2 months ago
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 211,250 shares of Class A common stock and restricted stock units (RSUs) for 105,125 shares of Class A common stock to sixteen (16) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
globenewswire.com
- 3 months ago
8. Profile
Summary
Vera Therapeutics, Inc. VERA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 1.48 B
Dividend Yield
0.00%
Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Contact
8000 Marina Boulevard, Brisbane, CA, 94005
https://veratx.com
IPO
Date
May 14, 2021
Employees
152
Officers
Ms. Debra Charlesworth
Vice President of Corporate Communications
Mr. David L. Johnson M.B.A.
Chief Opearating Officer
Dr. Marshall W. Fordyce M.D.
Founder, President, Chief Executive Officer & Director
Mr. Jason S. Carter
Chief Legal Officer
Ms. Emma Haywood
Vice President of Marketing
Mr. Joseph R. Young M.B.A.
Senior Vice President of Finance & Chief Accounting Officer
Dr. Allen Ebens B.Sc., Ph.D.
Executive Vice President of Research
Ms. Kelly Rauber
Senior Vice President of Human Resources
Mr. Sean P. Grant M.B.A.
Chief Financial Officer
Dr. Robert M. Brenner M.D.
Chief Medical Officer